Use during Pregnancy, Delivery or Lactation
Safety in the administration to pregnant or lactating women has not been established. Administration to these patients should be considered only if the expected therapeutic effect is judged to outweigh any possible risk. [In an animal (rats) study where a large dose of monoammonium glycyrrhizinate was administered there were findings of kidney malformation and the like.]
This website is intended for healthcare professionals only. To proceed, please indicate your PRC (Professional Regulation Commission) number for verification purposes.
By clicking "Continue," you consent to the collection and use of your PRC number and any other personal data provided for the purpose of confirming your professional credentials and accessing restricted content in this site. Your data will be handled in accordance with our Data Privacy Policy and applicable data protection laws.
If you do not consent to these terms, please exit the site.
Oops! We could not locate your form.